Spire Healthcare Group (LON:SPI) PT Raised to GBX 300

Spire Healthcare Group (LON:SPI) had its price target upped by equities research analysts at Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price would suggest a potential upside of 20.97% from the stock’s current price.

Separately, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 295 ($3.67) price target on shares of Spire Healthcare Group in a research report on Monday, February 26th.

Spire Healthcare Group Price Performance

LON:SPI opened at GBX 248 ($3.09) on Wednesday. The firm has a market cap of £1.00 billion, a PE ratio of 3,542.86, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a 12 month low of GBX 204 ($2.54) and a 12 month high of GBX 321.71 ($4.00). The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37. The company’s 50-day moving average price is GBX 237.57 and its two-hundred day moving average price is GBX 228.97.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.